CAR T Cell Therapy Services
Immunotherapy has become a brand new avenue of cancer therapy, independent of surgery, radio- and chemo-therapy. One of supply partners, Rockland, is making available its expertise for production of CAR-modified T and other immune cells using both viral and non-viral transfection methodologies.
Figure 1. A typical CAR T cell therapy involves four basic steps. (1) A patient or donor is leukapheresed to isolate peripheral blood mononuclear cells (PBMCs). (2) These cells are manipulated to express CAR by gene transfection. (3) CAR-expressing cells are differentiated into effector immune cells and expanded to sufficient number in vitro. (4) The CAR effector cells are then introduced into the patient. This is frequently done in conjunction with either chemo or radio therapy.
The basic CAR design consists of two fundamental domains: the extracellular antigen binding portion and the intracellular signaling portion. The antigen-binding domain is commonly composed of a single-chain variable fragment (scFv) derived from a monoclonal antibody (mAb). Common intracellular signaling domains include CD3ζ, CD28, 4-1BB and OX40.
CAR T Cell Therapy Services Offered
1. Cell-specific isolation, modification and expansion
2. CAR effector cell in vitro and in vivo functional analyses
Figure 2. Generations of CAR design. CAR is composed of extracellular antigen-binding domain scFv) and intracellular signaling domains, linked by a hinge and a transmembrane domain. The CD3ζ (red triangle) confers the cytotoxic effector function of CAR-T cells. CD28 (pale blue circle) is a co-stimulatory domain that is important for T cell proliferation and cytokine secretion. 4-1BB (yellow oval) is another co-stimulatory domain that promotes T cell survival and in vivo T cell persistence.
| Featured Products |
Application |
Size |
| Mouse IgG (H&L) Antibody Phycoerythin Conjugated Pre-Absorbed |
IF, FC |
1 mL |
| IL-2 Antibody |
ELISA, WB |
100 μg |
| IL-7 Receptor Alpha Chain Antibody |
ELISA, WB, IHC |
100 μg |
| IL-15 Antibody |
ELISA, WB |
100 μg |
| TNF alpha Antibody |
ELISA, WB, IHC |
100 μl |
| CD19 Allophycocyanin Antibody |
IHC, FC |
500 μL |
| CD19 Phycoerythrin Antibody |
FC |
500 μL |
| CD3 Allophycocyanin Antibody |
IHC, FC |
500 μL |
| CD3 Phycoerythrin Antibody |
FC |
500 μL |
| HER3 Antibody |
ELISA, WB, IP |
250 μg |
| EGFR Antibody |
ELISA, WB, IHC |
100 μg |
Ubiquitin Proteasome Pathway in Kidney Cancer: A Time for Novel Therapeutics
The Ubiquitin-Proteasome System (UPS) is heavily involved in many biological processes including cellular signaling, cellular homeostasis, and protein degradation. Due to the UPS' proliferation in most cellular function, it is not surprising to learn that many cancers are mediated by this pathway. Many researchers are investigating novel compounds and oncological drug candidates that specifically target the UPS, such as Bortezomib.
One of the most implicated UPS targets in renal cancer is SPOP (Speckle-type POZ Protein), a substrate-recognition subunit of the cullin-RING E3 ligase that influences cell cycle regulation, epigenetic control, and hormone signaling. Mutations in SPOP results in overexpression and mislocalization in renal cancers. Innovative therapies are being developed, most notably PROTAC® (Proteolytic Targeting Chimera) drugs, to degrade maladaptive proteins such as SPOP.
Contact us at Info@2BScientific.com for any enquiry